Literature DB >> 19851895

Clinicopathological analysis of primary epithelial appendiceal neoplasms.

Sachin Gupta1, Venkata Parsa, Volkan Adsay, Lance K Heilbrun, Daryn Smith, Anthony F Shields, Donald Weaver, Philip A Philip, Bassel F El-Rayes.   

Abstract

Appendiceal carcinomas are classified into three distinct histopathological disease entities: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), or peritoneal mucinous carcinomatosis with intermediate or discorant features (PMCA I/D). The treatment of appendiceal tumors should be based on accurate histopathological classification, per previously reported case series. The objective of this study was to evaluate the clinicopathologic presentation and outcome of patients with appendiceal tumors treated at our institution over a 15-year period. We identified patients with appendiceal tumors diagnosed or treated at our institution from January 1989 through May 2004. Chart review for age, gender, signs and symptoms at diagnosis, and treatment was performed. Review of the pathologic specimens was performed and tumors were classified as DPAM, PMCA I/D, or PMCA. Forty patients were identified (median age 52.5 years; males 38%). The number of patients with DPAM, PMCA I/D, and PMCA was 15 (38%), 6 (15%), and 18 (46%), respectively. Peritoneal involvement was seen in 11 (73%) of patients with DPAM, 5 (83%) of PMCA I/D, and 11 (61%) of PMCA. The median survival for patients with DPAM, PMCA I/D, and PMCA was 7.7 years (90% CI: 2.9--upper limit not estimable), 1.2 years (90% CI: 0.9-1.6), and 0.7 years (90% CI: 0.4-1.5), respectively. The difference in survival across the three groups was statistically significant. Three distinct histopathological disease entities exist in appendiceal tumors. The prognosis and management of these tumors should be based on the extent of disease and pathologic diagnosis.

Entities:  

Mesh:

Year:  2009        PMID: 19851895      PMCID: PMC3883058          DOI: 10.1007/s12032-009-9337-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  Pseudomyxoma peritonei.

Authors:  P H Sugarbaker; B Shmookler; B M Ronnett; D Chang
Journal:  Br J Surg       Date:  1999-06       Impact factor: 6.939

2.  71,000 HUMAN APPENDIX SPECIMENS. A FINAL REPORT, SUMMARIZING FORTY YEARS' STUDY.

Authors:  D C COLLINS
Journal:  Am J Proctol       Date:  1963-12

3.  Are there curative options to peritoneal carcinomatosis?

Authors:  Paul H Sugarbaker
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

Review 4.  Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Paul H Sugarbaker
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

Review 5.  Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification.

Authors:  Reetesh K Pai; Teri A Longacre
Journal:  Adv Anat Pathol       Date:  2005-11       Impact factor: 3.875

6.  Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Authors:  S González-Moreno; E Brun; P H Sugarbaker
Journal:  Ann Surg Oncol       Date:  2004-12-27       Impact factor: 5.344

7.  Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies.

Authors:  S J Connor; G B Hanna; F A Frizelle
Journal:  Dis Colon Rectum       Date:  1998-01       Impact factor: 4.585

8.  Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.

Authors:  Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger
Journal:  Am J Surg Pathol       Date:  2006-05       Impact factor: 6.394

Review 9.  New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?

Authors:  Paul H Sugarbaker
Journal:  Lancet Oncol       Date:  2006-01       Impact factor: 41.316

10.  Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy.

Authors:  John H Stewart; Perry Shen; Gregory B Russell; Robert F Bradley; Jonathan C Hundley; Brian L Loggie; Kim R Geisinger; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2006-03-14       Impact factor: 5.344

View more
  5 in total

Review 1.  Appendiceal Mucinous Neoplasms: Diagnosis and Management.

Authors:  Walid L Shaib; Rita Assi; Ali Shamseddine; Olatunji B Alese; Charles Staley; Bahar Memis; Volkan Adsay; Tanios Bekaii-Saab; Bassel F El-Rayes
Journal:  Oncologist       Date:  2017-06-29

2.  Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers.

Authors:  Walid L Shaib; Ludmila Katherine Martin; Minsing Choi; Zhengjia Chen; Kavya Krishna; Sungjin Kim; Edith Brutcher; Charles Staley; Shishir K Maithel; Philip Philip; Sherif Abdel-Misih; Tanios S Bekaii-Saab; Bassel F El-Rayes
Journal:  Oncologist       Date:  2015-06-12

3.  Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors.

Authors:  Ai-Tao Guo; Yan-Mi Li; Li-Xin Wei
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

4.  Cerebral metastasis from a previously undiagnosed appendiceal adenocarcinoma.

Authors:  Antonio Biroli; Paolo Cipriano Cecchi; Susanne Pragal; Esther Hanspeter; Andreas Schwarz
Journal:  Case Rep Oncol Med       Date:  2012-11-01

5.  Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis.

Authors:  Jason M Foster; Richard L Sleightholm; Steve Wahlmeier; Brian Loggie; Poonam Sharma; Asish Patel
Journal:  World J Surg Oncol       Date:  2016-09-13       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.